-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Verve Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2019 to 2023.
- Verve Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$50.1M, a 9.56% decline year-over-year.
- Verve Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$197M, a 2.19% decline year-over-year.
- Verve Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$200M, a 27.1% decline from 2022.
- Verve Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$157M, a 30.8% decline from 2021.
- Verve Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$120M, a 39.9% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)